AMGEN OBESITY GENE WEIGHS IN FAVORABLY IN JULY, STOCK GAINS 4-3/4 POINTS; BIOTECH BOOMS IN MONTH, WITH "F-D-C" INDEX PHARMACEUTICAL COMPONENT GAINING 9.5%
Executive Summary
The enthusiastic reception by investors of Amgen's preclinical work on the obesity gene is evidence that the luster is back on biotechnology
You may also be interested in...
Repurposing Leptin: How a “Fat Drug” Became a Model for a Leaner Industry
Two decades ago, the “fat dissolving” protein leptin was touted as one of the biggest opportunities in biotech—based on preclinical rodent studies. The compound may finally be making it to market in a very different model: as an orphan drug sponsored by Big Pharma.
Amgen Paying $1.3 Bil. For Tularik; Deal Brings Two Late-Stage Oncologics
Amgen is acquiring two late-stage oncology compounds through its $1.3 bil. buyout of Tularik
Amgen Paying $1.3 Bil. For Tularik; Deal Brings Two Late-Stage Oncologics
Amgen is acquiring two late-stage oncology compounds through its $1.3 bil. buyout of Tularik